Project Grant R43DK133006
Award Date
9/20/23
Completion Date
8/31/24
Dollars Obligated
$361K
Awardee
Oncotrap Inc. (KX22VNNMBYZ3)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate a novel adipokine as a potential therapeutic approach for resolving non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The total award amount is $469,235 and the project period runs from September 1, 2024 to June 30, 2028. The University of...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is funding research to define the role of antigen-specific T cell responses in non-alcoholic steatohepatitis (NASH). The $599,541 award, made on Sep 15, 2024, with a completion date of Aug 31, 2025, aims to: (1) determine the timing of T cell clonal expansion during NASH progression; (2)...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of novel small molecule modulators called Parmodulins to treat metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH). The $1,391,142 award to Function Therapeutics Inc. will fund research to synthesize and profile...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $293,543 to Furanica, Inc. to develop a novel compound, FAL-113, for the treatment of nonalcoholic steatohepatitis (NASH). The project aims to determine the mechanism of action, pharmacokinetics, and pharmacological efficacy of FAL-113 in preclinical NASH models. FAL-113 is designed to simultaneously modulate...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to understand the role of the unfolded protein response (UPR) in the development of non-alcoholic steatohepatitis (NASH), a leading cause of liver transplantation. The $172,060 award, granted on January 9, 2025, aims to elucidate the mechanisms by which the loss of the...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $675,480 project grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Fibrotherapeutics Inc. The funding supports the development of a novel, water-soluble, orally-active peptide derived from the caveolin-1 scaffolding domain (CSD) as a potential treatment for chronic kidney disease (CKD). The research aims to determine the therapeutic index, validate the...
This $707,389 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to evaluate the evolution of nonalcoholic fatty liver disease (NAFLD) during pregnancy and its influence on pregnancy outcomes. The study, titled "TARGETING NONALCOHOLIC FATTY LIVER DISEASE DURING THE REPRODUCTIVE PERIOD TO IMPROVE WOMEN'S HEALTH OUTCOMES,"...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $120,375 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to Childrens Hospital Medical Center in Cincinnati, Ohio. The grant, titled "Advanced Mouse Models of DDX41-Mutated Myelodysplastic Syndromes", will support the development of genetically-engineered mouse models to study the cellular and molecular mechanisms underlying myelodysplastic syndromes...
This federal Project Grant award of $806,452 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to investigate the mechanisms that combine type 2 diabetes (T2D) with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The research, led by The Children's Hospital Corporation (doing business as Boston Children's Hospital),...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research, supports Faknostics LLC's research into novel peptide-based inhibitors targeting the paxillin-FAK interaction as a potential treatment for liver fibrosis. The $651,952 award will enable Faknostics to optimize lead peptide candidates, characterize their biophysical and biochemical activity, and confirm...